Introduction
The proliferation of many hematopoietic precursor cells is promoted by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), stem cell factor, flt-2/3 ligand and other growth factors. [1] [2] [3] [4] [5] [6] Removal or depletion of these growth factors from cytokine-dependent cells results in apoptosis (programmed cell death). Hence some of these cytokines, eg GM-CSF and IL-3, are also referred to as survival factors. Once 'normal' hematopoietic cells lose their growth factor-dependency, they often become leukemic. [1] [2] [3] [4] [5] [6] The human TF-1 line is a multi-cytokine-dependent line (GM-CSF, IL-3) derived from a patient with an erythroleukemia. 7 TF-1 cells are multipotential as they can differentiate into either more mature erythroid, monocytic or megakaryocytic cells depending upon the differentiation stimulus. [7] [8] [9] This cell line has a low spontaneous frequency of conversion to factor independence and does not form tumors in immunocompromised mice. [7] [8] [9] [10] [11] [12] [13] Thus, this line permits analysis of aberrant oncogene expression on human hematopoietic cell growth, differentiation and malignant transformation.
GM-CSF and IL-3 exert their biological activity by binding to the GM-CSF and IL-3 receptors, respectively (GM-CSFR and IL-3R). [14] [15] [16] [17] These receptors are comprised of a ligand-specific ␣-subunit and a common ␤-subunit (␤ c ), which is essential for signal transduction.
14-17 GM-CSFR and IL-3R belong to the hematopoietin family of growth factor receptors and they lack an intrinsic tyrosine kinase activity. [14] [15] [16] [17] [18] The binding of these cytokines to their cognate receptors activates a Janus (Jak2) protein tyrosine kinase which leads to the phosphorylation and dimerization of signal transducers and activators of transcription (STATs). STATs, in turn regulate the expression of key genes involved in growth. 18 Activation of Jak2 by hematopoietic cytokines may occur by receptor aggregation leading to the multimerization of associated Jak proteins. In addition, after receptor ligation, the Shc protein becomes phosphorylated and forms a complex with the receptor. Shc then recruits the Grb2/Sos complex to the ␤ c chain resulting in activation of Ras. [18] [19] [20] [21] Activated Ras can then promote the sequential activation of Raf, MEK and MAP (ERK1 and ERK2) kinases (see Figure 16 ).
Recent studies have shown that hydrolysis of sphingomyelin to ceramide results in the activation of a ceramide-activated serine/threonine protein kinase (CAPK). 22 CAPK seems to correspond to a kinase suppressor of Ras (KSR) which was originally identified in Drosophilia and C. elegans. 23 The KSR kin-ase phosphorylates Raf-1 on threonine 261. Moreover, activated protein kinase C (PKC) has been shown to activate Raf. 20, [25] [26] [27] [28] Finally, there are Src-related tyrosine kinases which also activate Raf. 20, [24] [25] [26] [27] [28] [29] [30] Thus there are multiple, perhaps overlapping mechanisms to activate Raf and the MAP kinase cascade. Evidence suggests that this and other pathways involving phosphoinositol-3-kinase (PI 3 K) and p70S6 kinase are intimately associated with the control of the apoptotic machinery in myelo-monocytic cells. 17, 31 The mitogen-induced Ras-Raf signal transduction pathway evokes critical growth and differentiation signals in many cells. [19] [20] [21] The raf gene is conserved evolutionarily as raf alleles have been detected in numerous species including Drosophilia and C. elegans. [19] [20] [21] 32 There are three raf genes in mammals: A-raf, B-raf and raf-1. [19] [20] [21] 32 Raf kinases are essential components in signal transduction pathways which function in many different types of cells including hematopoietic cells. 17, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Anti-sense oligonucleotides to Raf-1 block cytokine-dependent growth indicating the necessity of Raf-1 activity in the proliferation and prevention of apoptosis in hematopoietic cells. 43 The Raf proteins have been dissected into three different functional domains; CR1, CR2 and CR3. The CR1 region contains the binding site for the activated Ras protein. 19, 20 The CR2 region negatively regulates the Raf kinase domain (CR3) which is located in the carboxyl terminus of Raf. 19, 20 Amino terminal deleted forms of these Raf proteins result in activated oncoproteins which can transform fibroblastic murine NIH-3T3 cells. [33] [34] [35] [36] Amino acids 340 and 341 of the wild-type p74Raf-1 protein are normally both tyrosine (YY) residues. 46, 47 Phosphorylation of these residues results in the activation of Raf-1 kinase. Moreover, mutation of these amino acids to aspartic acid (DD), which mimics a phosphorylated tyrosine, leads to constitutive Raf activation and transformation of NIH-3T3 cells. 46 In contrast, changing these regulatory amino acids to phenylalanine (FF), which can not be phosphorylated, results in a Raf protein with a reduced ability to transform NIH-3T3 cells. 35, 46 In addition, there are two serine residues adjacent to the regulatory region which are important in Raf-1 activity. 30 Finally, certain drugs have been shown to induce Raf dimerization and kinase activity. [48] [49] [50] Thus, there are different genetic and biochemical approaches to modulate Raf-1 activity.
The conserved phosphorylation regulatory residues in the wild-type A-Raf protein are tyrosines 299 and 300, 34, 35, 46 whereas the wild-type B-Raf protein contains aspartic acid residues at the conserved regulatory sites, namely positions 492 and 493. 34, 35, 46 Quantitative biochemical studies indicate that the B-Raf protein phosphorylates the MAP kinase kinase (MEK1) more efficiently than either the Raf-1 or A-Raf proteins. 35, [51] [52] [53] The B-Raf kinase is 50-fold more active than Raf-1 and approximately 500-fold more active than A-Raf. 35, 36, 47 It has been postulated that the aspartic acid residues present in the phosphorylation domain of B-Raf confer a very strong kinase activity. 34, 35, 46, 47 However, recent site-directed mutagenesis studies performed on these residues indicate that additional aspects of the B-Raf protein are also necessary for its high intrinsic kinase activity. 35 The roles that these individual Raf oncoproteins play in signal transduction and oncogenesis are not well understood. Mutated forms of the Raf oncogenes have been observed in diverse neoplasias including hematopoietic, breast, cervical, renal, laryngeal, hepatocellular and small cell lung carcinomas, and in lung biopsies recovered from cigarette smokers. [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] Mechanisms responsible for activating Raf expression include: point mutation, partial gene deletion, gene rearrangement and gene amplification. [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] In addition, there are also mutations that can eliminate Raf kinase activity. Man-made mutations which change the lysine in the ATP-binding site of the catalytic domain render the kinase inactive, and serve as dominant-negative mutations. 69, 70 Ras is one of the most frequently mutated oncogenes in human cancer. Approximately 50% of myelodysplastic syndromes have Ras mutations. [71] [72] [73] [74] Moreover, the tumor suppressor gene NF1, which downregulates Ras, is frequently mutated (lost) in juvenile CML. This results in constitutive Ras activation. 75, 76 Ras is therefore a clinically relevant target of many anti-neoplastic drugs which target leukemias. [77] [78] [79] [80] The Parke-Davis (Ann Arbor, MI, USA) compound PD98059 is a very specific and effective inhibitor of the MEK1 enzyme which lies immediately downstream of Raf. 79 Further understanding of this pathway may result in the identification of more efficacious anti-cancer therapies.
The ability of deregulated Raf expression to abrogate the cytokine dependency of certain murine hematopoietic cell lines has been examined. [81] [82] [83] Some investigations have indicated that a small frequency of the murine cytokine-dependent FDC-P1 cell line can be transformed to factor-independence after infection with retroviruses encoding v-Raf. 81 Other studies have shown that v-Raf expression did not abrogate the IL3 dependency of the murine 32D cell line. 82 However, enforced v-Raf expression did suppress apoptosis and promote growth in these cells. 82 We are interested in the transforming capacity of Raf since it is relatively inefficient in abrogating the cytokine dependency of hematopoietic cells, yet it is located at a critical position in both signal transduction and apoptotic pathways.
In the following study, the capacities of wild-type and activated Raf oncoproteins to abrogate the cytokine dependency of the human hematopoietic TF-1 cell line were examined. A gradient in the abilities of the different activated Raf proteins to abrogate cytokine dependency was observed as A-Raf was more efficient than either Raf-1 or B-Raf. Abrogation of cytokine dependency by the activated Raf oncoproteins was associated with autocrine growth factor synthesis. These studies demonstrate that deregulated Raf expression can abrogate the cytokine dependency of certain human hematopoietic cells and implicate an unexpected ability of the A-Raf kinase to promote growth.
Materials and methods

Cell lines and growth factors
The human TF-1 line 7 was purchased from the ATCC (Rockville, MD, USA) and grown in a humidified 5% CO 2 incubator with DMEM (Life Technologies, Gaithersburg, MD, USA) containing 5% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, GA, USA) supplemented with 1 ng/ml GM-CSF (R&D Systems, Minneapolis, MN, USA). Cytokine-independent HL60, U937, K562 and Jurkat cells were purchased from the ATCC (Rockville, MD, USA) and cultured in RPMI 1640 (Life Technologies) + 5% FBS. In some cases, Jurkat cells were treated with 10 U/ml recombinant IL-2 (Boehringer Mannheim, Indianapolis, IN, USA). Estradiol-dependent TF/⌬Raf:ER cells were grown in DMEM + 5% FBS + 1 m ␤-estradiol (Sigma, St Louis, MO, USA). ⌬Raf:ER-infected cells were also treated with ICI 164,384 which binds and inhibits the function of the native estrogen-receptor but is an activator of ⌬Raf:ER fusion proteins 33, 35 (Zeneca Pharmaceuticals, Macclesfield, UK). In some cases ⌬Raf:ER cells were also cultured with 4-OH Tamoxifen, also dissolved in ethanol (4-HT; Research Biochemicals, Natick, MA, USA) which is an estrogen-receptor antagonist but activates the ⌬Raf:ER fusion proteins. 34, 35 ⌬Raf:ER-infected cells were also treated with the MEK1 inhibitor PD98059 (New England Biolabs (NEB), Beverly, MA, USA) 80 which was dissolved in dimethyl sulfoxide (DMSO; Sigma). Control cultures were set up with DMSO and either GM-CSF or ␤-estradiol to measure the toxicity of the solvent. Cells were in some cases treated with the PKC inducing agent, 10 to 20 nm phorbol-12-myristate-13-acetate (PMA; Sigma) which was dissolved in DMSO.
Assays of cell growth, 3 H-thymidine incorporation and autocrine growth factor synthesis TF-1 and ⌬Raf:ER-infected TF-1 cells were washed three times with phosphate-buffered saline (PBS) before being set up for growth curves or proliferation assays. Growth curves were performed in 5 ml of medium with the indicated supplements in T25 tissue culture flasks (Corning, Elmira, NY, USA). Cell proliferation assays were performed in 96-well flat bottom plates (Corning) with initially 10 4 cells/well that were incubated for 3 days in the presence of the indicated supplements. During the last 6 h of incubation, cellular proliferation was assayed by adding 3 H-thymidine (6.7 Ci/mmol; NEN, Boston, MA, USA) as described. 10, 11, 82 The identities of the cytokines present in the supernatants of ⌬Raf:ER-infected TF-1 cells were determined by neutralization experiments with monoclonal antibodies (MoAb) to human GM-CSF and IL-3 (Genzyme, Boston, MA, USA) as described. 10, 82 Briefly, the supernatants were cultured for 1 h with either ␣GM-CSF or ␣IL-3 MoAbs before uninfected TF-1 cells were added. To determine the ability of the MoAbs to inhibit the growth of the ⌬Raf:ER-infected cells, the cells were incubated with the antibodies (200 g/ml) for 3 days, as in a normal proliferation assay. The cells were also cultured with an ␣-␤-galactosidase MoAb which was the same Ig class as the ␣GM-CSF and ␣IL-3 MoAbs. The levels of 3 H-thymidine incorporation observed with the MoAbs were normalized to the levels detected with the ␣-␤-galactosidase MoAb.
Polymerase chain reaction amplification of cytokine mRNA transcripts
Total cytoplasmic RNA was prepared as described 5 and 1 g was included in a 20 ml cDNA synthesis reaction containing: reverse transcriptase buffer, 1 mm of each dNTP, 20 mg/ml oligo-dT and 20 units Mo-MuLV reverse transcriptase. After incubation at 42°C for 40 min, the reaction was terminated by addition of H 2 O. For PCR amplification, 5 ml cDNA was included in a 50 ml reaction mixture containing PCR buffer, dNTP, 1-2 units Taq polymerase and 1 mm of each oligonucleotide primer. The primers for human GM-CSF were: CCTGGACTGGCTCCCAGCAG and GATGTGGCTGCA-GAGCCTGC defining a 425 bp fragment. The primers for human ␤-actin were: GAGAAGAGCTATGAGCTGCCT and TTCTGCATCCTGTCAGCAATG defining a 236 bp fragment. Twenty-five cycles of PCR were performed to detect the cDNAs. The PCR products were electrophoresed on 1% agarose gels and visualized after ethidium bromide staining of the gel. 35 and (10) pBP3, the empty retroviral puro r vector. Cells were also infected with the kinase-inactive pBP3⌬Raf-1 [301] :ER. 35 This mutant contains the K375W mutation which has a tryptophan (K) instead of a lysine (W) residue in the ATP binding site of the catalytic domain. 35 Puro r TF-1 cells were isolated in medium containing 2 g/ml puromycin (Sigma). TF-1 cells were infected with stocks recovered from the amphitropic PA317 packaging cell line as described. 82 The freshly infected cells were plated in GM-CSF-containing medium for 2 days. Then the cells were washed twice with PBS and then plated in the selective drug and either GM-CSF or ␤-estradiol. The cells were fed every 3 days with fresh medium. Wells positive for growth were enumerated 14 to 21 days post-infection. The nomenclature of the infected TF-1 cells is: TF/Raf-1, TF/⌬Raf-1, TF/⌬Raf-1:ER, TF/⌬A-Raf:ER, TF/⌬B-Raf:ER, TF/LNL6 and TF/pBP3 for cells infected with the Raf-1, ⌬Raf-1, ⌬Raf-1:ER, ⌬A-Raf:ER, ⌬B-Raf:ER, pLNL6, and pBP3 viruses, respectively. In subscripted brackets after the Raf gene are the amino acids present in the different Raf proteins at the regulatory phosphorylation residues [DD], [FF] or [YY] .
Retroviral infection of cells
Preparation of cell extracts and analysis by Western blotting
Cells were washed twice with cold PBS and lysed on ice in gold lysis buffer (GLB) containing 20 mm Tris (pH 7.9), 137 mm NaCl, 5 mm Na 2 EDTA, 1% (vol/vol) Triton X-100, 15% (vol/vol) glycerol, 1 mm phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, 1 m pepstatin A, 1 mm sodium orthovanadate, 1 mm ethylene glycol-bis (␤-aminoethyl ether)-N,N,NЈ,NЈtetra-acetic acid (EGTA), 10 mm sodium fluoride, 1 mm tetrasodium PP i , and 100 m ␤-glycerophosphate. Insoluble material was removed by centrifugation at 15 000 g as described. [33] [34] [35] All chemicals were purchased from Sigma unless otherwise indicated. Cellular proteins were analyzed by electrophoresis through polyacrylamide SDS gels followed by Western immunoblotting onto polyvinylidene difluoride membranes (PVDF, Immunobilon P; Millipore, Medford, MA, USA). Western blots were incubated with the appropriate primary Ab at a dilution of 1:1000 to 1:2000 and then washed in Tris-buffered saline containing 0.5% (vol/vol) Nonidet P-40. Antigen-antibody complexes were visualized by using 1:10 000-diluted goat ␣-rabbit antiserum, sheep ␣-mouse antiserum, or protein A coupled to horseradish peroxidase as indicated in the enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL, USA) as described. [33] [34] [35] The blots were exposed to Kodak XAR5 X-ray film (Kodak, Rochester, NY, USA) for 30 to 60 s.
Determination of Raf kinase activity
The cells were grown in phenol-red-free DMEM (Sigma) containing charcoal-stripped FCS and indicated supplements. Immune complexes of ⌬Raf:ER proteins were prepared by incubating cell lysates with ␣-hbER Ab (Santa Cruz Biotechnology (SCB), Santa Cruz, CA, USA) and protein A-sepharose beads. Immune complexes were collected, washed three times in lysis buffer, and the activities of ⌬Raf:ER were assessed by incubation for 30 min at 30°C in a reaction mix containing 25 mm HEPES (pH 7.4), 10 mm MgCl 2 , 1 mm DTT, 50 m ATP and 10 m ␥-32 P-ATP (3000 Ci/mmole, NEN) and 15 g of purified recombinant enzymatically inactive GST-MEK1[K97R] as a substrate as described previously. [33] [34] [35] The reactions were analyzed by polyacrylamide gel electrophoresis and electrotransfer. The membranes were exposed to X-ray film to quantitate GST-MEK1 phosphorylation and subsequently probed with an ␣-hbER Ab to quantitate the amount of the ⌬Raf:ER kinases present in each immunoprecipitate. Raf-1, A-Raf and B-Raf kinase activities were determined by performing a Raf kinase reaction on Raf proteins recovered after immunoprecipitation with antibodies specific for Raf-1, A-Raf and B-Raf (SCB). These kinase blots were subsequently probed with antibodies to the respective Raf kinase to quantitate the levels of Raf protein used in the kinase reactions.
Determination of MEK activity
MEK activity was measured by immunoprecipitating the MEK1 proteins overnight with an ␣MEK1 Ab (SCB) and protein Asepharose beads. The immunoprecipates were then used in a kinase reaction for 30 min at 30°C in a reaction mix containing: 100 mm HEPES pH 7.4, 25 mm MgCl 2 , 1 mm DTT, 50 m ATP, 10 m ␥-32 P-ATP and 2 g of bacterially expressed rp44, an enzymatically inactive form of MAP kinase (ERK2, NEB). The reaction mixtures were electrophoresed through a 10% polyacrylamide gel, transferred to PVDF and exposed to X-ray film.
Determination of p42/44
MAPK activity
Cells were deprived of either GM-CSF or ␤-estradiol for 24 h in phenol-red-free medium that contained 5% charcoalstripped FCS. Then the cells were pulsed with cytokine, dif- Isolation of low molecular weight DNA for apoptosis assays 1 × 10 7 cells (4 × 10 5 /ml) were grown in the different conditions for 2 days. The cells were pelleted by centrifugation, resuspended in 500 l of lysis buffer (20 mm Tris-HCl, pH 7.4, 10 mm EDTA, 0.2% Triton X-100) and placed on ice for 10 min. The lysate was then centrifuged for 10 min at 14 000 g, and the pellet was discarded. 10 l of 10 mg/ml protease K (Sigma) was added to the supernatant and the mixture was incubated overnight at room temperature. The solution was phenol-extracted twice followed by chloroform extraction once. The aqueous phase was saved each time. The nucleic acids were ethanol precipitated and subsequently resuspended in H 2 O. The concentration of the nucleic acids was determined, and 40 g was treated with 10 l of 1 mg/ml RNase A for 5-10 min. The remaining DNA was electrophoresced in an agarose gel with 1 × TBE (1 × = 0.09 m Tris borate, 0.002 m EDTA) running buffer and visualized with ethidium bromide.
Results
Expression of the three Raf oncoproteins and their immediate downstream targets in human hematopoietic cells
To determine the involvement of the Raf kinases and their downstream targets in hematopoietic cell growth, their presence and activities were examined in the HL60, TF-1, K562, U937 and Jurkat cell lines. Low levels of Raf-1 and A-Raf kinase activities were detected in HL60 cells after they had been deprived of serum for 24 h and then treated with DMSO (the vehicle for PMA) ( Figure 1 , panel a, lane 1) for 15 min. The levels of Raf-1 and A-Raf kinase activities increased upon exposure of the cells to PMA, serum or GM-CSF (panel a, lanes 2-4). A modest increase in B-Raf kinase activity was observed when HL-60 cells were treated with PMA. Slight increases in the already high level of MEK activities were seen when HL60 cells were incubated with PMA, FBS or GM-CSF. The Raf and MEK activity blots were subsequently probed with antibodies to each respective kinase to determine the levels of these proteins immunoprecipitated and used in the above kinase reactions. Roughly equal levels of the Raf and MEK proteins were detected in the cells grown in the different conditions. Phorbol ester stimulation of HL60 cells led to a pronounced increase in the amounts of activated MAPK (ERK1 and ERK2) detected (lane 2). The top portion of the same filter was probed with an antibody to p90
Rsk as a loading control.
Hyperphosphorylation of p90
Rsk was often observed by a Rsk kinase activities were determined in HL60, TF-1, K562, U937 and Jurkat cells. Raf kinase activities were determined after immunoprecipitation with antibodies specific for A-Raf, B-Raf or Raf-1. MEK assays were performed after immunoprecipitation with an ␣MEK1 antibody. These immunoprecipitation and subsequent kinase assays were performed in parallel with equal total protein concentrations. The levels of the Raf and MEK1 proteins immunoprecipitated were subsequently determined by probing the kinase filters with antibodies to each specific kinase. The presence of activated ERK1 and ERK2 was determined after probing protein extracts with a MAPK activation specific antibody. not result in a significant change in the levels of MEK activity under these culture conditions. In contrast, incubation of TF-1 cells with either PMA or GM-CSF led to a significant increase in the amount of activated ERK1 and ERK2 detected (lanes 2 and 3).
The cytokine-independent K562 line displayed an interesting pattern of Raf kinase expression (panel c). Relatively equal levels of Raf-1 kinase activity were detected when the serumstarved cells were treated either with DMSO or PMA for 15 min. High levels of A-Raf kinase activity were observed when the cells were cultured with DMSO, however, PMA treatment suppressed A-Raf kinase activity. In contrast, PMA induced B-Raf kinase activity in K562 cells. These observations were not due to differences in the amount of the individual Raf proteins immunoprecipitated in the experiments, as equal levels of the Raf proteins were observed after Western blotting. High levels of downstream MEK activity were detected in these cells. PMA induced the appearance of activated ERK1 and ERK2 and hyperphosphorylated p90
Rsk in these cells.
Relatively equal levels of Raf-1, A-Raf and B-Raf kinase activity were observed in the monocytoid cytokineindependent U937 cell line when the serum-starved cells were cultured with DMSO (lane 1) or PMA (lane 2) for 15 min. GM-CSF has been previously shown to induce Raf activity in U937 cells. 46 We wanted to determine whether U937 cells expressed A-Raf and B-Raf kinase activity. We observed higher levels of A-Raf kinase expression after GM-CSF treatment. In contrast, lower levels of Raf-1 and B-Raf kinase activity were observed after GM-CSF treatment. High levels of MEK activity were constitutively detected. Treatment of U937 cells with PMA led to an increase in activated ERK1 and ERK2 detected. Relatively high levels of Raf-1, A-Raf, B-Raf and MEK were observed in the serum-starved Jurkat T cell thymoma line that was cultured with DMSO, PMA, FBS or IL-2 (lanes 1-4). It has been shown previously that Jurkat cells express Raf-1 42 and B-Raf. 40 We have confirmed these results and shown that there are functional Raf kinase activities in these cells. Treatment of Jurkat cells with PMA resulted in the detection of activated forms of ERK1 and ERK2 and hyperphosphorylated p90
Rsk kinase (lanes 2 and 6). Thus, while the regulation of expression of Raf kinases in leukemic hematopoietic cells is complex, it is clear that Raf-1, A-Raf, B-Raf and their immediate downstream substrates (MEK, ERK1, ERK2 and p90 Rsk ) are expressed in these human hematopoietic cell lines.
Capabilities of different Raf oncoproteins to abrogate the growth factor dependency of the human hematopoietic TF-1 cell line
Little is known concerning the effects of aberrant Raf expression on the cytokine dependency of human hematopoietic cells. To determine whether the activated Raf proteins would relieve the cytokine dependency of human hematopoietic cells, TF-1 cells were infected with retroviruses encoding various Raf proteins, as well as the appropriate controls (Table  1) . No G418 r cells were isolated after a mock infection indi- Number of wells positive for growth/total number of wells examined. 1 × 10 5 cells were plated in each well of a 96-well plate 2 days postinfection in the presence of the indicated selective growth conditions. b LNL6 is a retroviral vector which lacks an oncogene. 83 The number of times the particular infection was done is indicated by the total number of wells Ϭ 96 (eg the mock infection was done 586 Ϭ 96 = 6 separate experiments). c All Raf genes in the experiments presented in this Table contained the wild-type amino acids in the regulatory phosphorylation residues. ND, not done.
cating that the selection conditions were sufficient to isolate stably infected cells (Table 1) . While G418 r cells were recovered after plating the empty retroviral (LNL6) vector-infected cells in GM-CSF + G418, no colonies were observed growing in the absence of GM-CSF. Cells growing in GM-CSF + G418 containing medium were isolated after infection of TF-1 cells with retroviruses encoding the wild-type Raf-1 (Raf-1), the 5Ј truncated Raf-1 (⌬Raf-1), or the truncated Raf-1 ligated to the estrogen-receptor hormone-binding domain (⌬Raf-1:ER). However, factor-independent cells (ie cells growing in the absence of exogenous GM-CSF (DMEM + G418) were not recovered after infection with the retrovirus encoding the wild-type Raf-1 protein indicating that over-expression of the normal Raf-1 protein did not abrogate cytokine dependency (Table 1 ). In contrast, after infection of TF-1 cells with a retrovirus encoding the activated Raf-1 protein (⌬Raf-1), cells growing in the absence of exogenous cytokines were recovered.
To determine whether the activated Raf protein present in the ⌬Raf-1:ER chimera would conditionally relieve the cytokine dependency of TF-1 cells, the infected cells were plated in the presence of ␤-estradiol + G418. Cells proliferating in the presence of ␤-estradiol were recovered indicating that activated Raf-1 expression could conditionally relieve cytokine dependency. The presence of ␤-estradiol was required, as factor-independent cells were not isolated when the TF/⌬Raf-1:ER cells were plated in the absence of ␤-estradiol (eg DMEM + G418).
To ascertain whether the activated A-Raf and B-Raf proteins would also abrogate cytokine dependency, TF-1 cells were infected with retroviruses encoding these oncoproteins. When the infected cells were plated in GM-CSF + G418, colonies were observed in 100% of the wells. In contrast, when the ARaf and B-Raf infected cells were plated in ␤-estradiol + G418, different efficiencies of cytokine dependency abrogation were observed. Estradiol-responsive cells were readily isolated from the ⌬A-Raf:ER-infected cells whereas they were less frequently retrieved from ⌬B-Raf:ER-infected cells. In summary, constitutive expression of the modified ⌬A-Raf:ER, ⌬Raf-1:ER and ⌬Raf-1 oncoproteins relieved the cytokine dependency of TF-1 cells, whereas the activated ⌬B-Raf:ER oncoprotein was less efficient. No cytokine-independent cells were recovered after infection with either the wild-type Raf-1 protein or the empty retroviral vector.
Effects of replacement of the amino acid residues in the Raf phosphorylation residues
To determine the importance of the Raf regulatory phosphorylation residues in the abrogation of cytokine dependency, they were altered by site-directed mutagenesis. 35 The cDNAs encoding the three activated Raf genes (⌬A-Raf:ER, ⌬B-Raf:ER and ⌬Raf-1:ER), as well as the mutants constructed by site-directed mutagenesis, were inserted into the pBP3 retroviral vector, 84 which contains the puro r gene encoding resistance to puromycin.
As controls, TF-1 cells were mock-infected, infected with either the empty retroviral vector pBP3 or a kinase-inactive ⌬Raf-1 [301] :ER mutant. When a mock-infected culture was plated in medium containing puromycin and either GM-CSF or ␤-estradiol, no colonies were observed indicating that the selection conditions were sufficient to isolate stably infected cells (Table 2 ). While cells were recovered that grew in medium containing GM-CSF + puromycin after infection with either the pBP3 empty retroviral vector or the kinase-inactive ⌬Raf-1 [301] :ER, no colonies were recovered that proliferated in medium containing ␤-estradiol + puromycin (Table 2 ). These results document that the puromycin selection protocol was effective and indicate that neither a kinase-inactive Raf-1 protein nor an empty retroviral vector could abrogate the cyto- Table 2 Effects of mutation of the critical phosphorylation residues in the Raf proteins on the ability to abrogate the cytokine dependency of TF-1 cells
Raf gene a,b,c
Selection conditions retroviruses/ml. a wt = wild-type amino acids residues are present at the phosphorylation residues. b Y = tyrosine, D = aspartic acid, and F = phenylalanine. c m = mutant amino acids residues are present at the phosphorylation residues. d Number of wells positive for growth/total number of wells examined. 1 × 10 5 cells were plated in each well of a 96-well plate 2 days post-infection in the presence of the indicated selective growth conditions. e pBP3 is a puro r retroviral vector which lacks an oncogene. 84 The number of times the particular infection was done is indicated by the total number of wells Ϭ 96.
kine dependency of TF-1 cells. After infection of TF-1 cells with puro r retroviruses encoding the ⌬A-Raf, ⌬B-Raf and ⌬Raf-1 proteins containing the normal wild-type amino acids present in the phosphorylation residues, cytokine-independent cells were isolated. The percentages of wells positive for growth in ␤-estradiol (Table 2) were similar to those observed with the pLNC based retroviruses presented previously in Table 1 .
When the tyrosines in the regulatory phosphorylation domains in Raf-1 or A-Raf were changed to aspartic acid, significant differences in the frequencies of isolation of cytokineindependent cells were not observed ( Table 2 ). The tyrosine to aspartic acid mutation is normally thought to result in Raf activation as the aspartic acid residues mimic an activated regulatory site. 34, 35, 45 However, the lack of a change in the levels of abrogation of cytokine dependency observed after infection with these mutants may not be that surprising as the frequencies of estradiol-responsive cells observed with the wild-type ⌬Raf-1 [YY] :ER and ⌬A-Raf [YY] :ER proteins were quite high and the chimeric proteins still need ␤-estradiol for activity. Alternatively, other residues may be important in the regulation of Raf activity as has been reported previously. 30 In contrast, when the ⌬Raf-1:ER or ⌬A-Raf:ER proteins contained phenylalanine residues in the phosphorylation regulatory sites, cytokine-independent cells were less frequently isolated. This mutation is normally thought to decrease the activity of the Raf-1 protein since the phenylalanine residues can not be phosphorylated. 34, 35, 46, 47 The situation with the ⌬B-Raf:ER oncoprotein was more complex as when the aspartic acid residues in B-Raf were mutated to either tyrosine or phenylalanine, cytokine-independent cells were recovered more readily (Table 2) . Thus, changing the wild-type aspartic acid residues in the B-Raf phosphorylation domain to other amino acid residues which have been associated with lower levels of B-Raf kinase activity actually increased the recovery of cytokine-independent TF-1 cells. A possible mechanism for this enhancement in the ability of these modified ⌬B-Raf:ER oncoproteins to abrogate cytokine dependency will be discussed later.
Efficiency of isolation of Raf-dependent TF-1 cells
While the above experiments indicated that the capability of the Raf proteins to abrogate the cytokine dependency of TF-1 cells differed, they did not determine the efficiencies by which the various Raf oncoproteins induced factor-independent growth. Since nearly all the wells cultured in GM-CSF + selective drug were positive for growth, more than one virus-infected TF-1 cell was present in many if not all the wells. To determine the differential plating efficiency of the infected cells, limiting dilution analyses were performed on pools of GM-CSF + drug selected cells ( Figure 2 ). As controls, the subcloning efficiencies of empty retroviral vector (pBP3) infected (panel a) kinase-inactive ⌬Raf-1 [301] :ER infected (panel b) and wild-type Raf-1 (panel c) infected TF-1 cells were examined. These pools of infected cells did not give rise to cells which grew in ␤-estradiol. In contrast, the cloning efficiency of these cells was approximately 1 when the cells were plated in the presence of exogenous GM-CSF.
Relatively high subcloning efficiencies of ⌬A-Raf [YY] :ER (panel f) and ⌬A-Raf [DD] :ER (panel d) infected cells were observed. Approximately one in five ⌬A-Raf [YY] :ER to one in ten ⌬A-Raf [DD] :ER infected cells would form a colony growing in response to ␤-estradiol (Table 3 ). The subcloning efficiency Limiting dilution analysis of ⌬Raf:ER-infected TF-1 cells. Ë, GM-CSF (1 ng/ml); ⌬, ␤-estradiol (1 m) and r, neither GM-CSF nor ␤-estradiol. (a) TF/pBP3, (b) TF/⌬Raf-1 [301] :ER (kinase-inactive), (c) TF/Raf-1, (d) TF/⌬A-Raf [DD] :ER, (e) TF/⌬A-Raf [FF] :ER, (f) TF/⌬A-Raf [YY] :ER, (g) TF/⌬B-Raf [DD] :ER, (h) TF/⌬B-Raf [FF] :ER, (i) TF/⌬B-Raf [YY] :ER, (j) TF/⌬Raf-1 [DD] :ER, (k) TF/⌬Raf-1 [FF] :ER, and (l) TF/⌬Raf-1 [YY] :ER. The cells were washed twice with PBS prior to plating out in medium containing GM-CSF or ␤-estradiol. Wells were fed fresh medium every 3 days. Clones positive for growth were enumerated after 14 to 21 days. Dotted line equals 37% of wells negative for growth from which the plating efficiency was estimated by the Poisson distribution. Solid arrow on the x-axis indicates where the experimental data line interacts with the 37% negative for growth line and is an estimate of the cloning efficiency. These experiments were performed on three to five pools isolated from each type of ⌬Raf:ER-infected cells.
of the ⌬A-Raf [FF] :ER-infected cells (panel e) was lower, as approximately 1 in 100 ⌬A-Raf [FF] :ER-infected cells proliferated in ␤-estradiol-containing medium (Table 3) . Thus, when the important tyrosine phosphorylation residues in A-Raf were changed to phenylalanine, a 20-fold decrease in the recovery of Raf-responsive cells was observed.
The plating efficiency of the ⌬B-Raf [DD] :ER-infected cells was low as only 1 in 1000 ⌬B-Raf [DD] :ER-infected cells formed a colony that grew in response to ␤-estradiol in the absence of exogenous GM-CSF (panel g). In contrast, approximately one in 300 ⌬B-Raf [FF] :ER (panel h) and one in 150 ⌬B-Raf [YY] :ER (panel i) infected TF-1 cells would form a colony Figure 2 . The intersections of the 37% wells negative for growth dashed line with the experimental plating ratio (solid line) and the X-axis provides an estimate of the cloning efficiency. b wt = wild-type amino acids at phosphorylation residues. c m = mutant amino acids at phosphorylation residues.
growing in response to ␤-estradiol. Thus, change of the phosphorylation residues in B-Raf from aspartic acid to either tyrosine or phenylalanine increased the recovery of cytokineindependent TF-1 cells (three-to seven-fold, respectively) ( Table 3) . Approximately one in 100 ⌬Raf-1 [YY] :ER-infected cells formed a colony growing in response to ␤-estradiol (panel l). A similar subcloning efficiency was observed with ⌬Raf-1 [DD] :ER-infected cells as one in 200 cells formed a colony in ␤-estradiol (panel j). Finally, the subcloning efficiency of the ⌬Raf-1 [FF] :ER-infected cells was examined (panel k). Approximately one in 600 ⌬Raf-1 [FF] :ER-infected TF-1 cells formed a colony growing in response to ␤-estradiol. Thus, changing the phosphorylation residues of Raf-1 to phenylalanine, decreased the ability of the ⌬Raf-1:ER protein to abrogate cytokinedependency (Table 3) .
Limiting dilution analysis indicated that the ⌬A-Raf [YY] :ER oncoprotein was 20-to 200-fold more efficient than either the ⌬Raf-1 [YY] :ER or ⌬B-Raf [DD] :ER oncoproteins, respectively, in relieving the cytokine dependency of TF-1 cells. Change of the tyrosine residues in either Raf-1 or A-Raf to phenylalanine resulted in a decrease in the recovery of estradiol-responsive cells by six-to 20-fold, respectively. In contrast, substitution of the aspartic acid residues in B-Raf with either phenylalanine or tyrosine, resulted in a three-to seven-fold increase, respectively, in the recovery of cytokine-independent cells.
Sensitivities of the ⌬Raf:ER-infected TF-1 cells to ␤-estradiol
Two different types of ⌬Raf:ER-infected TF-1 cells were isolated after drug selection, those that were recovered in medium containing either GM-CSF or ␤-estradiol. To begin to examine the differences between the two types ⌬Raf:ERinfected cells, the abilities of the cells to incorporate 3 H-thymidine in response to ␤-estradiol and GM-CSF were examined The pools of ⌬A-Raf [DD] :ER (panels d and g), ⌬A-Raf [FF] :ER (panels e and h) and ⌬A-Raf [YY] :ER-infected cells (panels f and i) which were isolated in selective drug and either GM-CSF or ␤-estradiol incorporated 3 H-thymidine in response to both GM-CSF and ␤-estradiol. Lower levels of 3 H-thymidine incorporation were observed in the ⌬A-Raf [DD] :ER and ⌬A-Raf [FF] :ER infected pools upon addition of ␤-estradiol, however these pools did incorporate 3 H-thymidine in dose-dependent fashions that were significantly above the background levels.
The pool of ⌬B-Raf [DD] :ER cells which had been recovered in GM-CSF + puromycin did not incorporate 3 H-thymidine upon culture with ␤-estradiol, but it did incorporate 3 H-thymidine in response to GM-CSF (panel j). A possible mechanism for this will be discussed later. The ⌬B-Raf [DD] :ER pool that had been isolated in ␤-estradiol + puromycin incorporated 3 H-thymidine upon addition of either ␤-estradiol or GM-CSF (panel m). The pool of ⌬B-Raf [FF] :ER-infected cells recovered in GM-CSF + puromycin-containing medium incorporated much more 3 H-thymidine in response to GM-CSF than ␤-estradiol (panel k). In contrast, the estradiol-selected pool incorporated relatively equal levels of 3 H-thymidine upon treatment with either ␤-estradiol or GM-CSF (panel n). The pools of ⌬B-Raf [YY] :ER-infected cells (panels l and o) recovered in medium containing puromycin and either GM-CSF or ␤-estradiol incorporated 3 H-thymidine when either GM-CSF or ␤-estradiol was added.
The pools of ⌬Raf-1 [DD] :ER (panels p and s) and ⌬Raf-1 [YY] :ER (panels r and u) infected cells which had been selected in puromycin and either GM-CSF or ␤-estradiol incorporated 3 H-thymidine in response to both ␤-estradiol and GM-CSF. In contrast the ⌬Raf-1 [FF] :ER-infected cells cultured with ␤-estradiol incorporated 3 H-thymidine in low levels which were above the background (panels q and t). These 3 H-thymidine incorporation assays indicated that ARaf and Raf-1 induced DNA synthesis in both GM-CSF-dependent and Raf-responsive ⌬Raf:ER-infected cells. In contrast, ⌬B-Raf [DD] :ER did not appear to exert a proliferative effect in the GM-CSF + puromycin selected cells as evidenced by the lack of 3 H-thymidine incorporation in response to ␤-estradiol. The change of tyrosine to phenylalanine in the regulatory phosphorylation domain of ⌬Raf-1:ER-infected cells decreased the ability of the cells to incorporate 3 H-thymidine upon addition of ␤-estradiol. Interestingly, substitution of the wild-type tyrosine residues with aspartic acid in A-Raf or Raf-1, which was shown previously to augment kinase activity, 36, 37 did not increase the levels of 3 H-thymidine incorporation observed. Finally, in some cases (eg ⌬A-Raf [YY] :ER, ⌬B-Raf [YY] :ER and ⌬Raf-1 [YY] :ER infected TF-1 cells), the cells that were maintained in ␤-estradiol were very sensitive to Raf activation and incorporated more 3 H-thymidine in response to ␤-estradiol than to GM-CSF stimulation.
Differential growth properties of the cytokinedependent vs ␤-estradiol-responsive ⌬Raf:ER-infected TF-1 cells
To measure the effects of the activated Raf kinases on the actual proliferation of the infected cells, growth curve studies [DD] :ER(GM)Pool, (e) TF/⌬A-Raf [FF] :ER(GM)Pool, (f) TF/⌬A-Raf [YY] :ER (GM)Pool, (g) TF/⌬A-Raf [DD] :ER(Est)Pool, (h) TF/⌬A-Raf [FF] :ER(Est)Pool, (i) TF/⌬A-Raf [YY] :ER(Est)Pool, (j) TF/⌬B-Raf [DD] :ER(GM)Pool, (k) TF/⌬B-Raf [FF] :ER(GM)Pool, (l) TF/⌬B-Raf [YY] :ER(GM)Pool, (m) TF/⌬B-Raf [DD] : ER(Est)Pool, (n) TF/⌬B-Raf [FF] :ER(Est)Pool, (o) TF/⌬B-Raf [YY] :ER (Est)Pool, (p) TF/⌬Raf-1 [DD] :ER(GM)Pool, (q) TF/⌬Raf-1 [FF] :ER (GM)Pool, (r) TF/⌬Raf-1 [YY] :ER(GM)Pool, (s) TF/⌬Raf-1 [DD] :ER(Est)Pool, (t) TF/⌬Raf-1 [FF] :ER(Est)Pool, and (u) TF/⌬Raf-1 [YY] :ER(Est)Pool. These experiments were performed on two to three different pools that were independently isolated from each type of ⌬Raf:ER-infected cell line and similar results were observed.
were performed on the pools of ⌬Raf:ER-infected TF-1 cells isolated in the presence of selective drug and either GM-CSF or ␤-estradiol. The extent of cell growth was measured by increases in cell number ( Figure 4) . As controls, the proliferation of the parental uninfected (panel a), the empty retroviral vector infected (panel b) and the kinase-inactive ⌬Raf-1 [301] :ER infected (panel c) TF-1 cells were examined. Consistent with the 3 H-thymidine incorporation assays presented earlier, these cells only grew in response to GM-CSF.
⌬Raf:ER-infected cells which had been recovered after plat-
Figure 4
Proliferation of ⌬Raf:ER-infected pools. Ì, GM-CSF (1 ng/ml), ⌬, ␤-estradiol (1 m), and r, no addition. (a) TF-1, (b) TF/pBP3puro(GM)Pool, (c) TF/⌬Raf-1 [301] :ER(GM)Pool, (d) TF/⌬A-Raf [DD] :ER(GM)Pool, (e) TF/⌬A-Raf [FF] :ER(GM)Pool, (f) TF/⌬A-Raf [YY] :ER(GM)Pool, (g) TF/⌬A-Raf [DD] :ER(Est)Pool, (h) TF/⌬A-Raf [FF] :ER(Est)Pool, (i) TF/⌬A-Raf [YY] :ER(Est)Pool, (j) TF/⌬B-Raf [DD] :ER(GM)Pool, (k) TF/⌬B-Raf [FF] :ER(GM)Pool, (l) TF/⌬B-Raf [YY] :ER(GM)Pool, (m) TF/⌬B-Raf [DD] :ER(Est)Pool, (n) TF/⌬B-Raf [FF] :ER(Est)Pool, (o) TF/⌬B-Raf [YY] :ER(Est)Pool, (p) TF/⌬Raf-1 [DD] :ER(GM)Pool, (q) TF/⌬Raf-1 [FF] :ER(GM)Pool, (r) TF/⌬Raf-1 [YY] :ER(GM)Pool, (s) TF/⌬Raf-1 [DD] :ER(Est)Pool, (t) TF/⌬Raf-1 [FF] :ER(Est)Pool, and (u) TF/⌬Raf-1 [YY] :ER(Est)Pool. These experiments were performed on two to three pools that were independently isolated from each type of ⌬Raf:ER-infected cells and similar results were observed.
ing in GM-CSF + selective drug only proliferated in response to GM-CSF. The inability of the GM-CSF + drug selected cells to grow in ␤-estradiol was somewhat surprising as some cells incorporated high levels of 3 H-thymidine in response to ␤-estradiol (Figure 3, panels f, l and r) . In contrast, the cells which had been selected to grow in ␤-estradiol + selective drug proliferated when either ␤-estradiol or GM-CSF was provided. Importantly, these estradiol-responsive cells did not proliferate in the absence of GM-CSF and ␤-estradiol indicating that their growth was conditional.
Raf prevents apoptosis in estradiol-responsive ⌬Raf:ER-infected TF-1 cells
To determine whether the activated Raf oncoproteins would prevent apoptosis, the infected cells were cultured in the presence and absence of GM-CSF or ␤-estradiol for 2 days. Apoptosis was measured by the appearance of a DNA fragmentation ladder ( Figure 5 ). The absence of low molecular weight DNA indicates that the cells have not undergone apoptosis. When the parental TF-1 cells were cultured in the absence of GM-CSF and ␤-estradiol for two days (lane 1) or in the presence of just ␤-estradiol (lane 3) the cells underwent apoptosis. In contrast, when the parental TF-1 cells were grown in GM-CSF, apoptosis was prevented (lane 2). Culture of the estradiol-responsive TF/⌬B-Raf [DD] :ER cells in the absence of GM-CSF and ␤-estradiol (lane 4) resulted in the cells undergoing apoptosis. In contrast, when the cells were plated in either the presence of GM-CSF (lane 5) or ␤-estradiol (lane 6), they did not undergo apoptosis ( Figure 5) . Thus, the activated ⌬B-Raf:ER oncoprotein prevented apoptosis in the Raf-responsive cells. When the GM-CSF-dependent TF/⌬B-Raf [DD] :ER cells were incubated in the absence of GM-CSF, apoptosis occurred (lane 7). However, apoptosis was prevented upon addition of GM-CSF (lane 8) but not ␤-estradiol (lane 9) to the growth medium. Thus, ␤-estradiol prevented apoptosis in the estradiol-responsive but not in the GM-CSF-
Figure 5
Prevention of apoptosis in estradiol-responsive TF/⌬B-RAF [DD] :ER cells. Low molecular weight DNAs were recovered from the cells cultured under the indicated conditions for 48 h. The cells had been washed three times with PBS before being cultured at 4 × 10 5 cells/ml in the indicated conditions. These experiments were also performed with 16 other GM-CSF-dependent and estradiolresponsive ⌬Raf:ER-infected cells and similar results were observed. dependent ⌬B-Raf [DD] :ER-infected hematopoietic cells. Similar differences with other pairs of estradiol-responsive vs GM-CSF-dependent ⌬Raf:ER-infected cells were observed in the ability of the other activated Raf oncoproteins to prevent apoptosis. These results were observed with ⌬Raf:ER constructs containing either wild-type or mutant amino acid residues at the phosphorylation sites. 3 
Stimulation of
H-thymidine incorporation by antiestrogens
To determine whether the effects on DNA synthesis were due to the activated Raf proteins and not the result of a nonspecific effect of ␤-estradiol, the ability of the anti-estrogen ICI 164,384 (ICI) to stimulate 3 H-thymidine incorporation in the estradiol-responsive ⌬Raf:ER-infected cells was examined ( Figure 6 ). ICI binds and inhibits the function of endogenous estrogen receptors, but it is an activator of ER fusion proteins. 33 
Differences in levels of Raf and MEK activities in GM-CSF-dependent vs estradiol-responsive ⌬Raf:ERinfected cells
To determine some of the biochemical differences between ⌬Raf:ER-infected cells that were estradiol-responsive vs those which were GM-CSF-dependent, the levels of Raf and the downstream MEK activities were compared (Figure 8 ). The cells were washed three times with PBS and then cultured for 24 h in the indicated conditions. Even though there remained some Raf activity in a significant percentage of the estradiolresponsive cells after 24 h, we did not deprive them of either GM-CSF or ␤-estradiol for longer periods of time as some of the cells would start to undergo apoptosis. Raf kinase assays were performed on the ␣hbER-immunoprecipitated ⌬Raf:ER proteins. Thus, the Raf activity detected was specific for the introduced ⌬Raf:ER construct. The Raf kinase assays, with the exception of those performed with TF/⌬B-Raf [FF] :ER cells (panels i and j), were exposed to autoradiographic film for 24 h (Figure 8) .
As a control, the levels of Raf were monitored in the ⌬Raf-
[301] :ER-infected cells (panel s). No Raf activity was observed when the cells deprived of GM-CSF and ␤-estradiol (lane 1).
A low level of Raf activity was seen in the TF/Raf-1 [301] :ER cells treated with GM-CSF for 24 h (lane 2). This results from GM-CSF inducing the activity of a kinase which phosphorylates and activates the ⌬Raf-1 [301] :ER, as detected in an in vitro kinase assay. The identity of this kinase is unknown and is Even though equal levels of total cell protein were immunoprecipitated, there could be varying amounts of ⌬Raf:ER proteins immunoprecipitated from cells cultured under the different conditions which could influence the levels of ⌬Raf:ER proteins or activities (Figure 8 ). When the TF/⌬Raf [301] :ER cells were incubated in the absence of GM-CSF or ␤-estradiol for 24 h (lane 9), very low levels ⌬Raf:ER proteins were seen. More ⌬Raf:ER protein was detected when the cells were stimulated to grow with GM-CSF (lane 10) than when they were cultured with either GM-CSF + ␤-estradiol (lane 11) or ␤-estradiol (lane 12) . This is in contrast to the results observed with the other cell lines examined as ␤-estradiol often increased the levels of chimeric ⌬Raf:ER proteins detected. In summary, while the kinase-inactive TF/⌬Raf-1 [301] :ER cells expressed the ⌬Raf:ER fusion protein, they did not display significant estradiol-inducible Raf or downstream MEK activity (Figure 8) .
The levels of Raf and MEK activities were examined in the different ⌬Raf:ER-infected cells that had been isolated in the presence of the selective drug and either GM-CSF or ␤-estradiol. The levels of the Raf kinase activities were usually higher in the estradiol-responsive than in the GM-CSF-dependent ⌬Raf:ER-infected cells (Figure 8 ). Raf kinase activity was observed in many of the estradiol-responsive cells even when they were starved of ␤-estradiol and GM-CSF for 24 h (exceptions were TF/⌬A-Raf [DD] :ER (panel b) and TF/⌬A-Raf [YY] :ER (panel f)). Higher levels of downstream MEK activity were often detected after ␤-estradiol treatment in the estradiolresponsive vs GM-CSF-dependent cells. Higher levels of ⌬Raf:ER proteins were also usually seen in the estradiolresponsive cells.
A striking result was observed with the ⌬B-Raf [DD] :ERinfected cells (panel g, lanes 1-4) . Virtually no Raf kinase activity was detected in the GM-CSF-dependent ⌬B-
Figure 8
Differences in the levels of Raf and Mek activities in ⌬Raf:ER cells that are GM-CSF vs estradiol-responsive. The levels of Raf and MEK kinase activities and ⌬Raf:ER proteins were compared in pools selected in puromycin and either GM-CSF or ␤-estradiol. Cell lysates were prepared as described in Materials and methods. GM-CSF and estradiol-responsive cells were washed three times with PBS and then cultured in phenol red-free medium in the presence and absence of GM-CSF or ␤-estradiol for 24 h as indicated on the bottom of the figure. The MEK assays were performed with the same samples. The Raf kinase immunoblots were subsequently probed with the ␣ER Ab (bottom panel) to determine the levels of ⌬Raf:ER protein. The autoradiographic exposure times for the Raf kinase activity was 24 h with the exception of the ⌬B-Raf [FF] :ER cells which was 4 h. The exposure times for MEK activity was 4 h. The chemiluminence time period to detect the ER protein was approximately 10 to 30 s. Raf and MEK kinase assays were performed with each pool two to six times and similar results were observed.
Raf [DD] :ER-infected cells even when they were cultured in GM-CSF + ␤-estradiol (lane 3) or ␤-estradiol (lane 4) which should promote ⌬Raf:ER activity (Figure 8 ). This is probably the reason why the GM-CSF-dependent ⌬B-Raf [DD] :ERinfected cells did not incorporate 3 H-thymidine in response to ␤-estradiol (Figure 3, panel j) . In contrast, Raf activity was observed in the pool of estradiol-responsive ⌬B-Raf [DD] :ERinfected cells (panel h).
Importance of the MEK1 pathway in the growth of the ⌬Raf:ER cells
To determine the biological significance of activation of downstream MEK activity, the effects of the MEK1 inhibitor PD98059 on 3 H-thymidine incorporation were examined in the estradiol-responsive TF/⌬Raf:ER cells ( Figure 9 , panels af). The MEK1 inhibitor suppressed GM-CSF-mediated To determine whether the MEK1 inhibitor also suppressed the proliferation of the ⌬Raf:ER-infected cells, growth curve experiments were performed (panels g-i). As controls, the cells were cultured with ␤-estradiol plus DMSO (the solvent for the MEK1 inhibitor). This treatment promoted the growth of the estradiol-responsive cells. However, when the cells were treated with the MEK1 inhibitor, the proliferation of the estradiol-responsive cells was inhibited and the cells died. These results indicated that the presence of a functional MEK1 signaling pathway was necessary for the estradiol-mediated growth and survival of ⌬Raf:ER-infected TF-1 cells.
The effects of the MEK1 inhibitor on relevant kinase activities were examined (Figure 10 ). Estradiol-responsive ⌬Raf-1 [YY] :ER cells were cultured in the presence of ␤-estradiol and either DMSO or PD98059. Treatment of the cells with ␤-estradiol and DMSO did not affect Raf or MEK activity or ERK2 activation. Activated ERK2 is more readily detected than activated ERK1 in estradiol-responsive ⌬Raf-1:ER-infected TF-1 cells with the activation specific Ab (see Figures 1 and 11) . The MEK1 inhibitor did not significantly suppress Raf activity, however, it did inhibit MEK and downstream ERK2 activity. 
Raf activates the downstream MAP kinase (ERK1 and ERK2) in ⌬Raf:ER-infected cells
To determine whether Raf induced MAP kinase (ERK1 and ERK2) activation, the ⌬Raf:ER-infected cells were cultured in the absence of GM-CSF or ␤-estradiol for 24 h and then pulsed with ethanol (the solvent for ␤-estradiol), ␤-estradiol or the positive control PMA for 15 min. Protein lysates were obtained and electrophoresced on gels, transferred to PVDF and then probed with the Ab which recognizes the activated forms of ERK1 and ERK2. Activated forms of ERK1 and ERK2 were not readily seen in the factor-deprived cells cultured in ethanol ( Figure 11, panel a) .
The effects of ␤-estradiol on ERK1 and ERK2 activation were examined on these cells (panel a). Activated forms of ERK1 and ERK2 were not detected in TF-1 cells infected with the kinase-inactive ⌬Raf-1 [301] :ER mutant after ␤-estradiol treatment (lane 1). In contrast, activated forms of ERK1 and ERK2 were seen after treatment of estradiol-responsive ⌬A-Raf [YY] :ER (lane 2), ⌬Raf-1 [YY] :ER (lane 3) and ⌬B-Raf [DD] :ER (lane 4) cells with ␤-estradiol for 15 min. After PMA stimulation, activated forms of ERK1 and ERK2 kinases were observed in all the cells. Relatively equal levels of p90
Rsk were detected in the sets of cells under the different treatment conditions.
A dose response curve experiment of ERK1 and ERK2 acti-
Figure 10
Effects of the MEK inhibitor on Raf, MEK and MAPK. Estradiol-responsive TF/⌬Raf-1 [YY] :ER cells were cultured in ␤-estradiol and either DMSO (lane 1) or PD98059 (40 m) (lane 2). Cell extracts were prepared and Raf and MEK activities determined. For determination of ERK1 and ERK2 activation, the cells were starved of ␤-estradiol for 24 h in the presence of PD98059 and then treated for 15 min with ␤-estradiol and then the activation of ERK1 and ERK2 determined. These experiments were performed twice and similar results were observed.
vation was performed in estradiol-responsive TF/⌬Raf-1 [FF] :ER (panel b) and TF/⌬B-Raf [FF] :ER (panel c) cells. Activated forms of ERK1 and ERK2 were not detected when the cells were cultured with ethanol (lane 1). Activated forms of ERK1 and ERK2 kinase were seen at doses of ␤-estradiol ranging from 625 to 10 000 nm (lanes 2-6). We wanted to determine whether the activation-specific ERK1 and ERK2 antibody would detect changes in the activation state of TF-1 cells infected with the weakest Raf-1 mutant as a control for the sensitivity of this antibody. Therefore we monitored the presence of activated ERK1 and ERK2 in GM-CSF-dependent and estradiol-responsive ⌬Raf-1 [FF] :ER cells. A time course for the appearance of activated forms of ERK1 and ERK2 was determined in GM-CSF-dependent (panel d) and estradiol-responsive (panel e) ⌬Raf-1 [FF] :ER cells. Ethanol did not induce the appearance of activated ERK1 or ERK2 (lane 1). Activated forms of ERK1 and ERK2 were not readily detected in the GM-CSF-dependent cells (panel d) after ␤-estradiol treatment. In contrast, activated forms of ERK1 and ERK2 were observed in these cells when they were treated with either PMA or GM-CSF (panel d). Estradiol-responsive ⌬Raf-1 [FF] :ER-infected cells displayed activated ERK1 and ERK2 approximately 15 min following ␤-estradiol treatment of the cells (panel e). Thus, the activated forms of ERK1 and ERK2 were more readily detected in the estradiol-responsive than in the GM-CSF-dependent ⌬Raf-1 [FF] :ER-infected cells.
MAPK (ERK2) activity in ⌬Raf:ER-infected cells
To determine the activities of the ERK2 kinase in the TF/⌬Raf:ER cells, an in vitro kinase assay was performed (Figure 12 ). In this in vitro kinase assay, ERK2 was immunoprecipitated with an ␣ERK2 Ab and MBP was used as a substrate. Kinase reactions were electrophoresed on gels, transferred to PVDF membranes and exposed to autoradiographic film for 2 h. As a control, ERK2 activity was measured in TF-1 cells which had been deprived of GM-CSF for 24 h and then treated with GM-CSF, ␤-estradiol or PMA for different time intervals (panel a). A basal level of ERK2 activity was detected in the starved cells. The level of ERK2 activity increased when the cells were treated with GM-CSF for 15 min and remained high for 2 h. Only a basal level of ERK2 activity was detected in cells cultured with ␤-estradiol. In contrast, PMA treatment of the cells led to a rapid and sustained (up to 8h) induction of ERK2 activity. Therefore, we measured ERK2 activity in the ⌬Raf:ER-infected cells at T 0 , 1, 4, 10 and 24 h after treatment with either GM-CSF or ␤-estradiol. ERK2 activity was measured in TF-1 cells infected with the kinase-inactive mutant as an additional control (panel b). The appearance of ERK2 activity in TF/⌬Raf-1 [301] :ER cells was delayed after GM-CSF treatment, as enhanced levels of ERK2 were only seen after 24 h. A slight increase in the ERK2 activity was seen 24 h after ␤-estradiol treatment of TF/⌬Raf-1 [301] :ER cells.
The levels of ERK2 kinase activity were examined in the TF-1 cells infected with the different ⌬Raf:ER genes. Interestingly, the level of ERK2 activity after GM-CSF or ␤-estradiol treatment was higher in the GM-CSF-dependent ⌬A-Raf:ER (panels c, e and g), ⌬B-Raf [DD] :ER (panel i) and ⌬B-Raf [FF] :ER (panel k) pools than in the ⌬Raf-1:ER (panels o, q and s) and ⌬B-Raf [YY] :ER (panel m) pools. These observations with ERK2 kinase activity were almost the opposite to that observed with the levels of ⌬Raf:ER protein activity detected as previously shown in Figure 8 .
A striking result was observed with the GM-CSF-dependent ⌬Raf-1:ER cells. As in kinase-inactive ⌬Raf-1 [301] :ER-infected cells (panel b), ERK2 activity was not detected 1-4 h after GM-CSF treatment. However, ERK2 activity was observed 10-24 h after GM-CSF treatment (panels o, q and s). In contrast, in the estradiol-responsive ⌬Raf-1:ER cells (panels p, r and t), ERK2 activity was detected prior to 10 h after both GM-CSF and ␤-estradiol treatment. To determine the effects of the MEK1 inhibitor on downstream ERK2 activity, some of the cells were co-cultured with the MEK1 inhibitor and subsequently treated with ␤-estradiol. Treatment of estradiol-responsive TF⌬B-Raf [DD] :ER (panel j) and TF/⌬Raf-1 [DD] :ER (panel p) cells with PD98059 suppressed downstream ERK2 activity.
In summary, ␤-estradiol induced ERK2 activity in all the estradiol-responsive ⌬Raf:ER-infected cells. Those GM-CSFdependent cells which expressed higher levels of the ⌬Raf:ER protein usually had delayed GM-CSF-inducible ERK2 activity when compared to the GM-CSF-dependent cells which expressed lower levels of the ⌬Raf:ER transgene. Thus certain overexpressed ⌬Raf-1:ER proteins may have functioned as
Figure 11
Raf activates MAP kinase in ⌬Raf:ER-infected cells. Active MAPK was examined with an anti-active MAPK antibody. (a) ERK1 and ERK2 activation in lanes: (1) TF/⌬Raf-1 [301] :ER(GM)Pool, (2) TF/⌬A-Raf: [YY] :ER(Est)Pool, (3) TF/⌬Raf-1 [YY] :ER(Est)Pool, and (4) TF/⌬B-Raf [DD] :ER(Est)Pool. The cells were deprived of growth factors and ␤-estradiol for 24 h and then treated with: solvent (ethanol), ␤-estradiol, or PMA. Equal loading of protein in the wells was determined by probing the blots with an ␣p90
Rsk antibody. (b) ERK1 and ERK2 activation in estradiol-responsive TF/⌬Raf-1 [FF] :ER cells which had been deprived of ␤-estradiol for 24 h and then treated with: ethanol, different doses of ␤-estradiol, PMA or GM-CSF. (c) ERK1 and ERK2 activation in estradiol-responsive TF/⌬B-Raf [FF] :ER cells which had been deprived of ␤-estradiol for 24 h and then treated with: ethanol, different doses of ␤-estradiol, PMA or GM-CSF. (d) ERK1 and ERK2 activation in GM-CSF-dependent TF/⌬Raf-1 [FF] :ER cells which had been deprived of GM-CSF for 24 h and then treated with: ethanol, 1000 nm ␤-estradiol for different time periods, PMA or GM-CSF for 15 min. (e) MAPK activation in estradiol-responsive TF/⌬Raf-1 [FF] :ER cells which had been deprived of ␤-estradiol for 24 h and then treated with: ethanol, 1000 nm ␤-estradiol for different time periods, PMA or GM-CSF for 15 min. These experiments were performed three times with similar results.
Figure 12
ERK2 activity in ⌬Raf:ER-infected ceIls. Time course experiments were performed to determine ERK2 activity in ⌬Raf:ER-infected cells. TF-1 cells were starved of GM-CSF for 24 h, then they were treated with GM-CSF, ␤-estradiol or PMA. The GM-CSF-dependent and estradiol-responsive ⌬Raf:ER-infected cells were deprived of either GM-CSF or ␤-estradiol for 24 h and then treated with GM-CSF or ␤-estradiol for the indicated time periods. In panels (b-t), the numbers above the lanes are the times (h) of stimulation of the cells with either ␤-estradiol (1 m) or GM-CSF (1 ng/ml). PD = PD98059 (40 m). These experiments were performed twice and similar results were observed. competitive substrates to inhibit ERK2 activity. This inhibition appeared to be lost in the estradiol-responsive cells. Moreover, the ERK2 activity detected in estradiol-responsive pools was in most cases higher than that detected in GM-CSFdependent pools which is consistent with our data using an anti-active ERK1,2 antibody. These findings suggest that ERK2 activation plays a pivotal role in determining cytokineindependent growth.
Growth factor secretion in the ⌬Raf:ER-infected cells
A possible mechanism by which the ⌬Raf proteins could promote growth is by an autocrine mechanism. To determine whether there were any autocrine growth factors released by ⌬Raf:ER-infected TF-1 cells, the supernatants from the Rafresponsive cells were titered on uninfected TF-1 cells ( Figure  13 ). As controls, the levels of 3 H-thymidine incorporation were also measured with different concentrations of either recombinant GM-CSF or ␤-estradiol (panel a). As expected, GM-CSF stimulated 3 H-thymidine incorporation in a dosedependent fashion whereas ␤-estradiol did not. Upon examination of the supernatants prepared from estradiol-responsive ⌬Raf:ER-infected cells, an activity was found which stimulated
Identification and biological significance of the autocrine growth factors secreted in the ⌬Raf:ERtransformed cells
To identify the autocrine growth factor(s) present in the ⌬Raf:ER-infected cells, the supernatants were treated with neutralizing monoclonal antibodies (MoAb) to GM-CSF and IL-3. A MoAb against human GM-CSF neutralized the activity present in the supernatants prepared from both ⌬A-Raf:ER and ⌬Raf-1:ER infected estradiol-responsive cells (Figure 14 , panels a and b). In contrast, treatment of the supernatants with an ␣IL-3 MoAb did not eliminate the activity which supported proliferation (data not presented). Raf-responsive ⌬B-Raf [DD] :ER and ⌬Raf-1 (lacking the ER domain) infected TF-1 cells also secreted GM-CSF.
To examine whether the GM-CSF expression was involved in the estradiol-responsive growth, the ability of an ␣GM-CSF
Figure 13
Detection of autocrine cytokines in estradiol-responsive cells. Positive and negative controls are presented in (a) s, rGM-CSF (starting concentration 500 pg/ml); b, ␤-estradiol (starting concentration 500 nm). Supernatants were prepared from (b) s, TF/⌬A-Raf [YY] :ER(Est)Pool, (c) s, TF/⌬B-Raf [DD] :ER(Est)Pool), (d) s, TF/⌬Raf-1 [YY] :ER(Est)Pool. TF-1 cells were cultured with the supplements for 3 days followed by incubation with 3 H-thymidine for the last 6 h. These experiments were performed six times and similar results were observed.
MoAb to inhibit proliferation was determined. Treatment of the TF/⌬A-Raf [YY] :ER(Est) cells with the ␣GM-CSF MoAb suppressed 3 H-thymidine incorporation two-fold (panel c). This response was specific as treatment of the cells with an anti-␤-galactosidase MoAb did not inhibit growth. Treatment of the cells with an anti-IL-3 MoAb also did not suppress 3 H-thymidine incorporation (data not presented).
The biological significance of the GM-CSF released by the ⌬A-Raf:ER and ⌬Raf-1:ER infected cells was further examined by determining the ability of the supernatants to support the proliferation of the uninfected parental cytokine-dependent line (panel d). The quantity of GM-CSF produced by the estradiol-responsive ⌬A-Raf:ER and ⌬Raf-1:ER-infected cells was sufficient to support the growth of TF-1 cells.
To determine whether the expression of the GM-CSF was related to the ability of the cells to grow in response to Raf activation in the absence of exogenous GM-CSF, RT-PCR was performed on pairs of GM-CSF-dependent and Raf-responsive cells ( Figure 15 ). As a positive control, the presence of GM-CSF cDNAs was determined in a cell line 11 which constitutively expresses the GM-CSF gene (lane 7). Either no or low levels of GM-CSF cDNAs were detected in the GM-CSFdependent ⌬Raf-1 [YY] :ER (lane 1), ⌬A-Raf [YY] :ER (Lane 3), ⌬B-Raf [YY] :ER (lane 5) infected cells. GM-CSF cDNAs were more readily detected in Raf-responsive ⌬Raf-1 [YY] :ER (lane 2), ⌬A-Raf [YY] :ER (lane 4), ⌬B-Raf [YY] :ER (lane 6) infected cells. Thus the ability of the ⌬Raf:ER-infected cells to grow in response to ␤-estradiol was associated with GM-CSF expression.
Discussion
The goals of this research were to investigate possible roles of Raf family members in hematopoietic cell growth, the effects of aberrant Raf expression on the cytokine dependency of human hematopoietic cells and the effects of certain tyrosine/aspartic acid residues on the ability of the Raf genes to abrogate cytokine dependency. The Raf-1, A-Raf and BRaf oncoproteins and the downstream MEK, MAPK (ERK1 and ERK2) and p90
Rsk proteins were expressed under certain circumstances in the human hematopoietic TF-1, HL-60, U937, K562 and Jurkat cell lines. It is interesting that all three Raf kinases are expressed in hematopoietic cells which suggests that they may have unique roles in regulating growth. These observations highlight the necessity to study the regulation of all three members of the Raf family. The GM-CSF-mediated proliferation of TF-1 cells was inhibited by the MEK1 specific inhibitor PD98059 further indicating the importance of this pathway in hematopoietic cell growth. Moreover, activation of hormone-inducible forms of the A-Raf, B-Raf and Raf-1 kin- The creation of conditionally activated Raf proteins by fusing the enzymatic region of the Raf protein to the ER hormone binding domain has allowed a more thorough and comprehensive analysis of the roles of Raf in the transformation process. With these inducible Raf proteins, we have been able to ascertain that the Raf oncoproteins were necessary for the proliferation of the estradiol-responsive cells. Furthermore, these conditional kinases have allowed us to determine that there are differences in the levels of Raf, MEK and MAPK (ERK1 and ERK2) kinase activities in cells isolated in selective drug and either GM-CSF or ␤-estradiol. Higher expression of the Raf and downstream kinases was often linked with Rafresponsive growth. This result is important to consider in gene transfer experiments. The levels of transgene expression may be relatively low in cells isolated in the presence of just the selectable drug. In contrast, when cytokine-independence or cellular transformation is selected for, higher levels of transgene expression may be required. Furthermore, certain inactive ⌬Raf-1:ER oncoproteins may actually inhibit the activity of downstream kinases as these ⌬Raf-1:ER proteins may serve as dominant-negatives in certain biochemical reactions.
There are qualitative and quantitative differences in the abilities of Raf-1, A-Raf and B-Raf proteins to phosphorylate different proteins involved in Raf-mediated signal transduc-
Figure 15
Differences in the levels of GM-CSF cDNAs in RAFresponsive and GM-CSF-dependent ⌬Raf:ER-infected cells. All RT-PCR reactions were performed the same day under identical conditions. The first two samples were run on one gel and samples 3-7 were run on a different gel the same day. The expression of GM-CSF and ␤-actin were monitored by RT-PCR in pairs of GM-CSF-dependent and Raf-responsive cells. Lanes: (1) TF/⌬Raf-1 [YY] :ER (GM Pool), 2) TF/⌬Raf-1 [YY] :ER (Est Pool), (3) TF/⌬A-Raf [YY] :ER (GM Pool), (4) TF/⌬A-Raf [YY] :ER (Est Pool), (5) TF/⌬B-Raf-1 [YY] :ER (GM Pool), (6) TF/⌬B-Raf-1 [YY] :ER (Est Pool) and (7) TF/GM+LTR-2, a cell line which was engineered to constitutively express GM-CSF. 11 This experiment was repeated twice and similar results were observed.
tion. 34, 35, 46, 48 An end result of these divergent activities may lead to inherent differences in the abilities of these Raf proteins to abrogate the cytokine dependency of hematopoietic cells. The ⌬B-Raf:ER oncoprotein is more effective in inducing transformation of fibroblastic NIH-3T3 and Rat-1 cells than either ⌬Raf-1:ER or ⌬A-Raf:ER. 34, 35 In NIH-3T3 cells, B-Raf is also a more effective kinase in phosphorylating the downstream MEK1 substrate than either Raf-1 or A-Raf. 34 ,35,46,48 ⌬B-Raf:ER also stimulated higher levels of heparin-binding epidermal growth factor (HB-EGF) mRNA accumulation than either ⌬Raf-1:ER or ⌬A-Raf:ER in NIH-3T3 cells. 35 Thus, in fibroblastic cells, B-Raf has very strong activities in various biochemical and transformation assays. We also observed that in estradiol-responsive ⌬B-Raf:ER-infected TF-1 cells, higher levels of Raf and MEK activities were often seen than in ⌬Raf-1:ER or ⌬A-Raf:ER infected cells (Figure 8 and data not presented). However, this is a point of diversion between NIH-3T3 and TF-1 cells, as ⌬B-Raf:ER did not induce higher levels of MAP kinase or GM-CSF secretion than either ⌬A-Raf:ER or ⌬Raf-1:ER.
⌬A-Raf:ER was the most effective Raf protein in abrogating the cytokine dependency of TF-1 cells. A similar pattern of abrogation of cytokine dependency has been observed with the murine FDC-P1 cell line (Hoyle et al, manuscript in preparation). Higher levels of GM-CSF expression were observed in estradiol-responsive TF/⌬A-Raf [YY] :ER than in TF/⌬Raf-1 [YY] :ER or TF/⌬B-Raf [DD] :ER cells as determined by sensitive 3 H-thymidine incorporation assays (Figure 11 ). The anti-estrogen ICI 164,384 also induced higher levels of 3 Hthymidine incorporation in the TF/⌬A-Raf [YY] :ER than in the TF/⌬Raf-1 [YY] :ER or TF/⌬B-Raf [DD] :ER cells. Finally the estradiol-responsive growth of TF/⌬A-Raf [YY] :ER cells was more sensitive to the MEK1 inhibitor PD98059 than either TF/⌬Raf-1 [YY] :ER or TF/⌬B-Raf [DD] :ER. Thus, an activated ⌬A-Raf:ER protein stimulated certain aspects of TF-1 cell proliferation better than either an activated ⌬Raf-1:ER or ⌬B-Raf:ER protein.
It will be relevant to know whether there are different substrates activated or inactivated by the different ⌬Raf:ER kinases in these cells.
The lack of efficient abrogation of cytokine dependency by ⌬B-Raf:ER was not due to a defect in the recombinant retrovirus which would prevent transgene expression, as Raf activity was detected in the rare estradiol-responsive ⌬B-Raf:ER-infected cells recovered. It may be that high levels of B-Raf are not tolerated well in hematopoietic cells and only a few 'mutant' cells can grow in response to ⌬B-Raf:ER activation. In these 'mutant' estradiol-responsive cells, high levels of Raf and downstream MEK were observed (Figure 8 ). It will be important to determine if there are other alterations in signaling pathways activated in ␤-estradiol vs GM-CSF dependent ⌬B-Raf:ER-infected cells. It is also conceivable that ⌬B-Raf:ER is normally conducting the cells to a differentiation/death pathway rather than to a survival pathway.
Recently, it was shown that high levels of the ⌬Raf-1:ER kinase will induce the expression of the p21
Cip1 protein which serves to shut down cell cycle progression by interfering with cyclinD/cdk2 activity. 85 ⌬Raf-1:ER induced more p21 Cip1 than ⌬A-Raf:ER in NIH-3T3 cells. 85 Thus, high levels of Raf activity may in some cases negatively affect cell cycle progression and cell proliferation. Studies are in progress to determine whether there are differences in the levels of p21
Cip1 induced by ⌬B-Raf:ER, ⌬Raf-1:ER and ⌬A-Raf:ER in the GM-CSF-dependent vs estradiol-responsive cells.
The roles of regulatory phosphorylation residues on the ability of the Raf proteins to abrogate the cytokine dependency of TF-1 cells were examined. Change of the tyrosine amino acids in Raf-1 or A-Raf to aspartic acid residues did not appear to result in a significant increase or decrease in the recovery of cytokine-independent TF-1 cells. Although these modifications, in some cases, resulted in increased Raf kinase activity (eg ⌬Raf-1 [DD] :ER, shown in Figure 8 ), they did not lead to a higher frequency of estradiol-responsive cells. Some of these mutations may not readily exert their effects in the chimeric oncogene:ER system as ␤-estradiol is required for the activity of these proteins. Dimerization initiated by ␤-estradiol may induce Raf activity as some drugs which induce dimerization activate Raf. [48] [49] [50] However, change of these tyrosine residues in A-Raf and Raf-1 to phenylalanine led to a substantial decrease in the abilities of the ⌬A-Raf:ER and ⌬Raf-1:ER oncoproteins to abrogate the cytokine dependency of TF-1 cells. Therefore, ⌬A-Raf:ER and ⌬Raf-1:ER require either tyrosine or aspartic acid residues to be present at the phosphorylation residues for effective abrogation of cytokine dependency of TF-1 cells. However, this is not an absolute requirement as cytokine-independent cells were recovered from ⌬Raf-1 [FF] :ER and ⌬A-Raf [FF] :ER infected cells. The contribution of ␤-estradiol induced dimerization of the Raf constructs may be important in the ability of these [FF] mutants to abrogate the cytokine dependency of TF-1 cells. Alternatively, the adjacent serine residues, which have been shown to function in regulation of Raf-1 activity, 30 may be sufficient to confer a sufficient low level of transforming activity to the mutant Raf constructs which contain phenylalanine.
In contrast, the above scenario was almost reversed with the ⌬B-Raf:ER oncoprotein as change of the wild-type aspartic acid residues to either tyrosine or phenylalanine increased the recovery of cytokine-independent TF-1 cells. Very low levels of ⌬B-Raf [DD] :ER kinase activity were detected in the GM-CSFdependent ⌬B-Raf [DD] :ER-infected cells. This may indicate that deregulated wild-type B-Raf kinase activity is tightly regulated in TF-1 cells and most TF-1 cells can not tolerate increased levels of B-Raf kinase activity. Decreasing the activity of the B-Raf kinase may have augmented its ability to abrogate the cytokine dependency of hematopoietic cells. Alternatively, these amino acid substitutions may confer a structure to B-Raf which modifies the kinase activity and enhances its ability to abrogate cytokine dependency.
A central and still unresolved question is why are there three different Raf kinases expressed in hematopoietic cells? Do they have identical, similar or overlapping functions? Do they differentially induce the activation of regulatory proteins that are either stimulatory or inhibitory? Since all three Raf kinases are expressed in hematopoietic cells, it is unlikely that they have identical functions. Moreover studies with knockout mice indicate that the different Raf genes will not compensate for each other, since in many cases the disruption of a particular Raf gene was lethal or had severe developmental defects. 86, 87 The three Raf proteins may affect cell growth, cell cycle progression, apoptosis and differentiation by different mechanisms. Alternatively, they may vary in the degree of stimulating cell growth vs induction of p21
Cip1 and prevention of cell cycle progression. Thus, the different Raf proteins may sit on a teeter-totter to equilibrate cell cycle progression and apoptosis. This may make the development of Raf kinase inhibitors more difficult as specific inhibitors for each Raf kinases may have to be made. However, if specific inhibitors are identified, they will be very promising pharmacological agents in the treatment of leukemias.
Recently, it was shown that NIH-3T3 cells transformed by the ⌬Raf-1:ER oncogene secrete an autocrine growth factor for fibroblast and other cells, namely HB-EGF. 35, 88 It has also been shown in certain human breast cancer cell lines that overexpression of Raf-1 leads to estrogen-independent growth, which is associated with a poorer clinical prognosis. 89 It is interesting that the Raf-mediated transformation of both fibroblasts and human hematopoietic cells resulted in the expression of autocrine cytokines. This is not an artifact of culturing the ⌬Raf:ER-infected cells in ␤-estradiol, since factor-independent ⌬Raf-1 infected TF-1 cells, also secrete GM-CSF. ⌬A-Raf:ER-infected cells expressed the highest levels of cytokines which would prevent apoptosis. The reason why particular Raf genes induce more GM-CSF expression than other Raf genes is unknown. The GM-CSF expression in the ⌬Raf:ER-transformed cells was biologically relevant, as it was sufficient to support the proliferation of the parental cells. This cytokine expression may serve to induce additional signal transduction pathways (eg Jak, STAT) which promote proliferation. A model for the autocrine growth promoted by activated Raf oncoproteins is presented in Figure 16 .
The presence of relevant key signaling molecules are included in this diagram. Interestingly, mutations are not observed frequently, if at all, at the GM-CSF receptor ␣ and ␤ chains in hematopoietic malignancies. [90] [91] [92] This may indicate that these mutations are lethal. However, mutations have been observed at many downstream targets. Mutations have been observed at Jak in immunodeficient patients. 93 Constitutive activation of the Jak/STAT proteins has been observed in T cell leukemias transformed with HTLV-I. 94, 95 Myelodysplastic syndromes often have mutations at Ras. [71] [72] [73] [74] [75] NF-1 is a tumor suppressor gene which is often deleted or altered in juvenile CML. 74, 75 The Shc gene is located at chromosome 1q21, which is often involved in neoplasia-associated changes. 96 The Grb2 gene is often aberrantly expressed in human neoplasia, especially breast cancer. 97, 98 Grb2 is located at 17q22 which is duplicated in certain tumors. [96] [97] [98] These diverse mutations may subsequently affect the activity of Raf and the downstream MAP kinase cascade. There are additional mechanisms to activate Raf and the MAP kinase cascade. PKC is activated by diacyl glycerol (DAG) and some PKC isoforms are activated by ceramide. 99 Certain PKC isoform activate Raf. [24] [25] [26] [27] Some thyroid tumors have PKC mutations. 100, 101 Thus, many key components of the signaling pathways resulting in Raf activation are mutated or aberrantly expressed in certain human tumors. Raf induced downstream MEK activity, and this activity was necessary for growth as the MEK1 inhibitor PD98059 suppressed ⌬Raf:ER-mediated proliferation. Activated forms of ERK1 and ERK2 were observed after stimulation of the estradiol-responsive cells. However, there is no proof that ERK1 or ERK2 activation was necessary for ⌬Raf:ER-mediated growth. Transfection of these cells with dominant-negative ERK1 and ERK2 mutants may help to answer this important question. Moreover, this pathway becomes even more complex as in some experimental systems, activated ERK1 and ERK2 may exert negative feedback on its upstream activator, MEK. 102 The activated ERK1 and ERK2 kinases could either directly modify transcription factors which regulate GM-CSF transcription or activate p90
Rsk which subsequently phosphorylates transcription factors and controls GM-CSF transcription. Constitutively activated ERK2 mutants have been shown to activate the production of IL-3, GM-CSF and IL-4 in T cells.
p90
Rsk was activated by PMA in certain hematopoietic cells, however, we did not detect a mobility shift which is indicative of p90
Rsk activation in estradiol-treated ⌬Raf:ER-infected cells. It may be that the level of activated p90
Rsk activated by ␤-estradiol is too low to be detected by a mobility shift. An in vitro kinase assay is being developed as a more sensitive approach to measure p90
Rsk activation after ␤-estradiol or GM-CSF treatment. One target of p90
Rsk is the CREB transcription factor which binds CRE elements that are contained in the GM-CSF promoter. 104 In addition, CREB activates the expression of Fos, a component of the Ap-1 binding complex. p90
Rsk will also activate Fos. Alternatively, there could be unknown targets induced by MEK which induce GM-CSF transcription and autocrine transformation. These potential MEK substrates are indicated by question marks on Figure 16 .
This situation with Raf-mediated growth is even more complex as there may be both positive and negative effects which are modulated by ⌬Raf:ER expression. We have observed that ⌬Raf:ER induced GM-CSF expression which subsequently stimulated CIS (cytokine inducible sequence) mRNA accumulation in FDC-P1 cells transformed to grow in response to ⌬Raf-1:ER activation (unpublished observations). CIS is a member of a family of Jak inhibitors which have negative effects on cell growth as they serve to extinguish the activated Jak proteins. [105] [106] [107] [108] In addition there are other proteins such as MAP kinase phosphatase-1 (MKP-1) which function to inactivate ERK1 and ERK2. MKP-1 normally serves to inactivate the MAP kinase pathway after the signal has been transduced for an appropriate time period. Abnormal regulation of MKP-1 has been associated with the malignant transformation of prostate cells. 109, 110 Thus, cells have evolved elaborate fine tuning to limit the response to cytokines and mitogens.
Additional studies will be necessary to determine whether the Raf-induced GM-CSF expression occurred by transcriptional or post-transcriptional mechanisms. The GM-CSF promoter contains regulatory regions which are recognized by transcription factors (eg NF-AT, AP-1, CREB, ELF-1) which could potentially be regulated by Raf or the downstream MAP kinases. [111] [112] [113] [114] Further elucidation of the mechanism by which Raf stimulates the autocrine production of cytokines may result in the identification of therapies which target autocrinetransformed hematopoietic cells. There are a number of studies which implicate the effects of transcription factors on
Figure 16
Model for autocrine transformation of TF-1 cells due to activated RAF expression. Purple = inactive protein, green = activated protein or compound, black = inhibitory protein or compounds. − = inhibition of step. PL = phospholipid, DAG = diacylglycerol. The tyrosines (Y) and phosphates (P) on the ␤ c chain are not meant to indicate donation of a phosphate group. They are meant to indicate which regions of the ␤ c receptor are responsible for activation of Jak and Shc proteins.
hematopoietic cell growth, differentiation and malignant transformation. [115] [116] [117] [118] [119] [120] Since Raf induces a regulatory cascade which results in the phosphorylation of certain transcription factors, it is also a relevant target for the development of antineoplastic drugs.
Finally, Raf may promote cell growth by modulating the activity of pro-and anti-apoptotic proteins. 44, [121] [122] [123] [124] Raf may induce the phosphorylation of the Bad protein which makes Bad disassociate from Bcl-2 and associate with the 14-3-3 family of proteins. 123, 124 This allows Bcl-2 to associate with Bax which is normally pro-apoptotic, and results in the prevention of apoptosis. Raf-1 can also associate with the 14-3-3 family of proteins. It may be that Raf-1, Bad, 14-3-3 and unknown proteins form a complex which subsequently results in the phosphorylation of Bad. It will be important to determine whether the different Raf proteins vary in their ability to form such a complex.
These cells provide a rich source to study the effects of a critical oncogene involved in a central signal transduction pathway. The unique and common roles of the three different Raf kinases on signal transduction, cell cycle progression, apoptosis and differentiation can be investigated with these cells. In addition, these cells provide a relevant model to evaluate the abilities of anti-cancer drugs which target Raf and the downstream MEK/MAP kinase cascade to alter their activity and promote terminal differentiation of leukemic cells.
